- Immutep (IMM) says its final trial results have given it confidence that its drug can deliver clinical improvement for cancer patients
- 227 patients with metastatic breast cancer took part in a randomised, placebo-controlled study, evaluating Immutep’s lead product candidate eftilagimod alpha (efti) in combination with paclitaxel chemotherapy
- The trial showed patients in the efti group had a median overall survival of 20.4 months, compared to 17.5 months for patients in the comparator group
- The research data will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021
- Immutep shares fell 16.4 per cent, trading at 58.5 cents at 1:04 pm AEDT
Immutep (IMM) said its final trial results have given it confidence its drug can deliver clinical improvement for cancer patients.
The company received final results from its Phase IIb Active Immunotherapy Paclitaxel (AIPAC) trial.
Under the trial, 227 patients with HER2-negative/HR positive metastatic breast cancer took part in a randomised, placebo-controlled study. The trial evaluated Immutep’s lead product candidate eftilagimod alpha (efti) in combination with paclitaxel chemotherapy, compared to a combination of placebo and paclitaxel chemotherapy.
The trial showed patients in the efti group had a median overall survival of 20.4 months, compared to 17.5 months for patients in the comparator group.
The combination of efti and paclitaxel chemotherapy was also declared safe and well tolerated.
Immutep CEO Marc Voigt said the results have given the company additional confidence that efti can ultimately deliver a meaningful clinical improvement for diverse sets of cancer patients.
“The results from our AIPAC trial are especially pleasing because metastatic breast cancer patients in the chemotherapy setting are a difficult to treat and large patient population where immunotherapies often fail to provide an additional benefit,” Mr Voigt said.
The data is being presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021, running from November 10 to 14.
Immutep is now preparing a Phase III investigation of efti in combination with paclitaxel in metastatic breast cancer.
Immutep shares fell 16.4 per cent, trading at 58.5 cents at 1:04 pm AEDT.